title: [Nuclear factor I-C inhibits platelet-derived growth factor-induced enhancement of dermal fibroblast sensitivity to TGF-β].
abstract: OBJECTIVE
  To investigate the effect of nuclear factor I-C (NFI-C) on platelet-derived growth factor (PDGF)-induced up-regulation of TGF-β receptor II (TβRII) in dermal fibroblasts.
  
  
  METHODS
  A lentiviral vector containing NFI-C sequence (Lenti-GFP-NFI-C) was transfected into a human foreskin fibroblast cell line (HFF-1). Cultured HFF-1 cells, cells transfected with Lenti-GFP-NFI-C, and cells transfected with a negative virus were stimulated with PDGF-BB, and Western blotting and RT-qPCR were used to detect the expression levels of TβRII in the treated cells.
  
  
  RESULTS
  PDGF treatment significantly increased the expression level of TβRII in HFF-1 cells (P<0.05). The cells transfected with Lenti-GFP-NFI-C expressed a significantly lower level of TβRII than non-transfected cells in response to PDGF stimulation (P<0.05), but the negative virus showed no such inhibitory effect (P>0.05). No significant difference was found in the expression level of TβRII protein between cells transfected with Lenti-GFP-NFI-C-transfection before PDGF stimulation and the blank control cells.
  
  
  CONCLUSIONS
  NFI-C can inhibit PDGF-induced up-regulation of TβRII and thus reduce the sensitivity of the dermal fibroblasts to TGF-β.
authors.affiliation: Department of Plastic Surgery, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China.E-mail: zlp982440@163.com.
authors.forename: Liangping
authors.initials: L
authors.lastname: Zhang
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Rui
authors.initials: R
authors.lastname: Lei
authors.forename: Hui
authors.initials: H
authors.lastname: Shen
authors.forename: Yichen
authors.initials: Y
authors.lastname: Shen
authors.forename: Zhinan
authors.initials: Z
authors.lastname: Wu
authors.forename: Jinghong
authors.initials: J
authors.lastname: Xu
mesh_terms: D000077214:Becaplermin; D002460:Cell Line; D005347:Fibroblasts / Q000187:drug effects*; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus; D051839:NFI Transcription Factors / Q000235:genetics*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D020574:Proto-Oncogene Proteins c-sis; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D015854:Up-Regulation
chemical_list: D051839:NFI Transcription Factors; C497647:NFIC protein, human; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D000077214:Becaplermin; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II